Latest AL-S Pharma News & Updates

See the latest news and media coverage for AL-S Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

AL-S Pharma

Biotechnology company developing antibody therapy for ALS

al-spharma.com

Founded year: 2016
Company type: Private company
Number of employees: 11–50
Industry: Pharmaceuticals

Last updated October 26

Latest news about AL-S Pharma

In short: AL-S Pharma announced positive AP-101 Phase 2 results and appointed Harry Welten CEO in 2026.

Company announcements

September 28 AL-S Pharma

AL-S Pharma announces AP-101 Phase 2 results webinar

Dr. Genge shares safety and clinical data for the SOD1-targeting antibody, with a Phase 3 trial planned for 2027.

August 30 AL-S Pharma

AL-S Pharma details AP-101 Phase 2 results and Phase 3 plans

The antibody targets toxic SOD1 proteins to slow ALS progression and achieved primary safety endpoints, supporting a 2027 Phase 3 trial launch.

April 27 AL-S Pharma

AL-S Pharma discusses AP-101 Phase 2 data

Chief Medical Officer Angela Genge highlights survival improvements and biomarker reductions in ALS patients. Next steps follow Phase 2 success.

December 5, 2025 AL-S Pharma

AL-S Pharma reports positive Phase 2 AP-101 results

Primary safety and tolerability endpoint was met, with prolonged survival, delayed ventilatory support, functional stabilization, biomarker improvement, and plans for a confirmatory Phase 3 study.

Media coverage

October 26 Finanznachrichten

AL-S Pharma AG: AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual Meeting

New Phase 2 post-hoc analyses demonstrate greater body-weight preservation with AP-101 compared with placebo in patients with ALS Findings reinforce clinical relevance of body weight...

October 13 The Pharma Letter

AL-S Pharma names finance veteran Harry Welten CEO as ALS antibody heads to Phase III

Switzerland's AL-S Pharma, a biotech developing antibodies against misfolded proteins in amyotrophic lateral sclerosis (ALS), has appointed Harry Welten as chief executive, succeeding Michael Salzmann...

April 23 PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

AL-S Pharma has released new data from the phase 2 trial evaluating its drug AP-101 in patients with amyotrophic lateral sclerosis (ALS). ALS is a...

March 18 MarketWatch

Additional Phase 2 Data of AL-S Pharma's Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

The MarketWatch News Department was not involved in the creation of this content. Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six...

Never miss news about AL-S Pharma

Track AL-S Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AL-S Pharma competitors & trending companies

Browse news for competitors to AL-S Pharma and other trending companies.